RT Journal Article
SR Electronic
T1 Bayesian modeling for the detection of adverse events underreporting in clinical trials
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.18.20245068
DO 10.1101/2020.12.18.20245068
A1 Barmaz, Yves
A1 Ménard, Timothé
YR 2021
UL http://medrxiv.org/content/early/2021/05/12/2020.12.18.20245068.abstract
AB Introduction Safety underreporting is a recurrent issue in clinical trials that can impact patient safety and data integrity. Clinical Quality Assurance (QA) practices used to detect underreporting rely on on-site audits, however adverse events underreporting remains a recurrent issue. In a recent project, we developed a predictive model that enables oversight of Adverse Event (AE) reporting for clinical Quality Program Leads (QPL). However, there were limitations to using solely a machine learning model.Objective Our primary objective was to propose a robust method to compute the probability of AE underreporting that could complement our machine learning model. Our model was developed to enhance patients safety while reducing the need for on-site and manual QA activities in clinical trials.Methods We used a Bayesian hierarchical model to estimate the site reporting rates and assess the risk of underreporting. We designed the model with Project Data Sphere clinical trial data that is public and anonymized.Results We built a model that infers the site reporting behavior from patient-level observations and compares them across a study to enable a robust detection of outliers between clinical sites.Conclusion The new model will be integrated into the current dashboard designed for clinical Quality Program Leads. This approach reduces the need for on-site audits, shifting focus from source data verification (SDV) to pre-identified, higher risk areas. It will enhance further quality assurance activities for safety reporting from clinical trials and generate quality evidence during pre-approval inspections.The preprint version of this work is available on MedRxiv: https://doi.org/10.1101/2020.12.18.20245068Key pointsSafety underreporting is a recurrent issue in clinical trials that can impact patient safety and data integrityWe used a Bayesian hierarchical model to estimate the site reporting rates and assess the risk of underreporting.This model complements our previously published machine learning approach and is used by clinical quality professionals to better detect safety underreporting.Competing Interest StatementYves Barmaz and Timothé Ménard were employed by Roche at the time this research was completed.Funding StatementFunding for development and testing of the safety reporting model was supplied by Roche.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable for this researchAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data can be accessed on the Project Data Sphere website. https://github.com/ybarmaz/bayesian-ae-reporting/blob/main/data.csv https://data.projectdatasphere.org/projectdatasphere/html/content/104